The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic breast cancer (MBC): A multi-institutional analysis.
 
Zachary William Neil Veitch
No Relationships to Disclose
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst); SignalChem (Inst)
 
Patricia A. Tang
Consulting or Advisory Role - AMGEN; AstraZeneca; Celgene; Genomic Health International; Merck; Novartis Canada Pharmaceuticals Inc; Shire; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen
Other Relationship - Novartis
 
Jessica L. Conway
No Relationships to Disclose
 
Domen Ribnikar
No Relationships to Disclose
 
Hamzeh Albaba
No Relationships to Disclose
 
Karen M. King
No Relationships to Disclose
 
Sasha M. Lupichuk
No Relationships to Disclose
 
David W. Cescon
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Genomic Health; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Roche/Genentech (Inst)